Crohn`s Disease (CD) Therapy

Global Crohn`s Disease (CD) Therapy Market to Reach US$17.7 Billion by 2030

The global market for Crohn`s Disease (CD) Therapy estimated at US$13.3 Billion in the year 2024, is expected to reach US$17.7 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. Anti-TNF Biologics, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$7.4 Billion by the end of the analysis period. Growth in the Aminosalicyates segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 4.5% CAGR

The Crohn`s Disease (CD) Therapy market in the U.S. is estimated at US$3.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 4.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.8% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Crohn`s Disease (CD) Therapy Market - Key Trends and Drivers Summarized

Combating Crohn`s Disease: What`s New in CD Therapy?

Crohn`s Disease (CD) therapy has evolved significantly, moving beyond traditional symptom management to more targeted approaches aimed at modifying the disease course and improving quality of life. Advances in medical research have led to the development of biologic therapies that specifically target proteins and pathways involved in inflammation. These include TNF inhibitors, integrin inhibitors, and interleukin inhibitors, which have shown efficacy in reducing symptoms and achieving remission in many patients. Additionally, the use of immunomodulators in combination with biologics has become a common strategy to enhance therapeutic outcomes and minimize side effects.

How Are Emerging Therapies Transforming Treatment Paradigms in CD?

Emerging therapies in CD focus on new targets within the immune system and the gut microbiome, which play crucial roles in the pathogenesis of the disease. JAK inhibitors, a newer class of small molecule drugs, have shown promise in treating moderate to severe CD by blocking key enzymes involved in the inflammatory process. Moreover, fecal microbiota transplantation (FMT) and the use of probiotics are being explored to restore intestinal microbiome balance, offering a novel approach to therapy that could potentially lead to better disease management and remission rates.

What Challenges Persist in the Management of Crohn`s Disease?

Despite advancements, managing CD remains challenging due to its complex nature and variability in symptoms and treatment responses among patients. One of the biggest challenges is the chronic relapsing-remitting pattern of the disease, which can complicate long-term management strategies and affect patient adherence to treatment. Additionally, the risk of complications such as strictures, fistulas, and colorectal cancer requires ongoing monitoring and sometimes surgical intervention, adding to the disease burden. Furthermore, the cost of newer therapies, particularly biologics, can be prohibitively high, limiting access for many patients.

What Drives the Growth in the CD Therapy Market?

The growth in the CD therapy market is driven by several factors. An increasing incidence of inflammatory bowel diseases globally and greater awareness of CD are key factors contributing to the growing demand for effective treatments. Advances in diagnostic techniques allow for earlier and more accurate diagnosis, facilitating timely treatment initiation. The development of novel therapeutics that offer improved efficacy and safety profiles also stimulates market expansion. Additionally, rising healthcare expenditure and better healthcare infrastructure, particularly in developing countries, enhance access to advanced therapies, further driving market growth.

SCOPE OF STUDY:

The report analyzes the Crohn`s Disease (CD) Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Segment (Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars, Other Segments)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 46 Featured) -

• AbbVie, Inc.
• Amgen, Inc.
• AstraZeneca PLC
• Biogen, Inc.
• Boehringer Ingelheim International GmbH
• Celltrion Healthcare Co., Ltd.
• ChemoCentryx, Inc.
• Ferring Pharmaceuticals
• Johnson & Johnson
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Novo Nordisk A/S
• Pfizer, Inc.
• Takeda Pharmaceutical Co., Ltd.
• UCB SA

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.